Hung Do

Callidus Biopharma, Inc. develops drug discovery services. The firm focuses on enzyme replacement therapies (ERTs) for lysosomal storage disorders (LSDs). Its novel technology platform is based on attaching a form of the naturally occurring Insulin-like growth factor (IGF-2) to enhance the targeting of therapeutic enzymes to the relevant cells in the body. The company was founded by Cuong Viet Do and Hung Do in 2010 and is headquartered in Bensalem, PA.

Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA.

Novazyme Pharmaceuticals, Inc. researches and develops methods for modifying recombinantly produced enzymes. It develops a series of novel protein engineering technologies that have been shown in pre-clinical studies to greatly enhance the targeting and uptake of replacement enzymes. Novazyme's technologies also have application for developing advanced monoclonal antibodies and gene therapies. The company is located in Oklahoma City, OK.